Compare HBIO & CIF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HBIO | CIF |
|---|---|---|
| Founded | 1901 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Trusts Except Educational Religious and Charitable |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.8M | 31.1M |
| IPO Year | 2000 | N/A |
| Metric | HBIO | CIF |
|---|---|---|
| Price | $0.71 | $1.74 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 43.9K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.11% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $87,371,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.22 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.28 | $1.47 |
| 52 Week High | $2.36 | $1.77 |
| Indicator | HBIO | CIF |
|---|---|---|
| Relative Strength Index (RSI) | 54.36 | 56.15 |
| Support Level | $0.71 | $1.68 |
| Resistance Level | $0.78 | $1.75 |
| Average True Range (ATR) | 0.07 | 0.02 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 38.12 | 72.29 |
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.
Mfs Intermediate High Income Fund is a United States based diversified closed-end management investment company. Its investment objective is to seek high current income but may also consider capital appreciation. The fund invests a majority of its net assets, including borrowings for investment purposes, in high-income debt instruments. Its portfolio of investments includes investment grade corporate bonds, government securities and other securities.